A detailed history of Geode Capital Management, LLC transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 517,008 shares of SLS stock, worth $610,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares
517,008
Previous 273,063 89.34%
Holding current value
$610,069
Previous $275,000 123.64%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$1.06 - $1.63 $258,581 - $397,630
243,945 Added 89.34%
517,008 $615,000
Q1 2024

May 13, 2024

BUY
$0.51 - $1.55 $14,004 - $42,563
27,460 Added 11.18%
273,063 $275,000
Q4 2023

Feb 13, 2024

BUY
$0.88 - $1.57 $8,800 - $15,700
10,000 Added 4.24%
245,603 $260,000
Q3 2023

Nov 13, 2023

BUY
$1.42 - $1.83 $67,502 - $86,992
47,537 Added 25.28%
235,603 $386,000
Q4 2022

Feb 13, 2023

BUY
$1.8 - $5.41 $78,024 - $234,507
43,347 Added 29.95%
188,066 $443,000
Q2 2022

Aug 12, 2022

BUY
$2.14 - $4.15 $16,741 - $32,465
7,823 Added 5.71%
144,719 $322,000
Q1 2022

May 13, 2022

BUY
$4.73 - $7.18 $14,639 - $22,222
3,095 Added 2.31%
136,896 $914,000
Q3 2021

Nov 12, 2021

BUY
$8.21 - $10.53 $266,529 - $341,845
32,464 Added 32.04%
133,801 $1.23 Million
Q2 2021

Aug 13, 2021

BUY
$7.19 - $13.71 $46,231 - $88,155
6,430 Added 6.78%
101,337 $1.12 Million
Q1 2021

May 12, 2021

BUY
$5.5 - $11.71 $332,706 - $708,361
60,492 Added 175.77%
94,907 $810,000
Q4 2020

Feb 12, 2021

SELL
$2.45 - $17.66 $64,922 - $467,972
-26,499 Reduced 43.5%
34,415 $199,000
Q3 2020

Nov 13, 2020

BUY
$1.88 - $3.58 $564 - $1,074
300 Added 0.49%
60,914 $161,000
Q2 2020

Aug 13, 2020

BUY
$1.53 - $3.93 $11,975 - $30,760
7,827 Added 14.83%
60,614 $177,000
Q1 2020

May 14, 2020

BUY
$1.7 - $4.08 $1,591 - $3,818
936 Added 1.81%
52,787 $91,000
Q4 2019

Feb 13, 2020

BUY
$3.79 - $10.5 $196,515 - $544,435
51,851 New
51,851 $222,000

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $24.3M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.